Company intelligence / Profile preview

Epsilogen

London, England, United Kingdomepsilogen.com ↗

Ownership: Private
Development stage: Other

Overview

MOv18 IgE—the world’s first therapeutic anti-cancer immunoglobulin E antibody—has completed a phase I trial in folate receptor alpha-positive cancers with a favorable safety profile and early signs of clinical activity. The company’s pipeline now includes both clinical-stage and preclinical assets targeting solid tumors using novel engineered antibody formats that leverage the unique properties of multiple immunoglobulin classes.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)IgE antibodiesIgA antibodies (via TigaTx acquisition)Hybrid/engineered antibody formats combining IgE, IgA, and IgG functionalities
Industry: Biotech

Drug pipeline

7 assets

MOv18 IgE

6 more assets in the full pipeline.

Partnerships

Not explicitly listed, but investors include Novartis Venture Fund which may indicate strategic relationships.

Beyond the preview

Go deeper on Epsilogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epsilogen.